Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Drug adherence low in pregnant women with RA

24 Nov 2019

Women with rheumatoid arthritis (RA) appear to have low utilization of medications safe to take during pregnancy, commonly discontinuing their medications in the first trimester, a recent study has found.

The study used population-based administrative data and included 1,730 singleton pregnancies in 1,301 women with RA (mean age at delivery, 31.4 years). Researchers evaluated the utilization of RA medications, such as conventional synthetic disease modifying antirheumatic drugs (csDMARDs), biologics, glucocorticosteroids (GCs) and nonsteroidal anti-inflammatory drugs (NSAIDs) during 24 and 12 months prior to conception, each trimester of pregnancy, and 12 months after delivery.

With regard to medication use, the most frequently used csDMARDs throughout the perinatal period were antimalarials (20.8 percent before conception, 7.8 percent during pregnancy and 13.1 percent postpartum) and sulfasalazine (8.4 percent, 2.3 percent and 4.6 percent). Methotrexate was the second most frequently used csDMARD before conception (10.9 percent), but this dropped to <1 percent during pregnancy.

Use of ciclosporin, gold, leflunomide and minocycline prior to conception was also low at 0.6 percent, 2.8 percent, 1.0 percent and 2.4 percent, respectively, with a further decline during pregnancy. Biologics used were predominantly antitumour necrosis factor inhibitors (anti-TNFs; 4.3 percent prior to conception, 1.9 percent during pregnancy and 4.5 percent postpartum). Pattern of use was similar for GCs and NSAIDs.

The rate of medication discontinuation was high in the first trimester of pregnancy, particularly that of antimalarials (57.3 percent), azathioprine (59.1 percent), sulfasalazine (69.5 percent) and biologics (50.8 percent).

Factors associated with discontinuation of antimalarials in the first trimester included maternal age (odds ratio [OR], 0.90, 95 percent confidence interval [CI], 0.86–0.95) and number of rheumatology visits (OR, 0.86, 95 percent CI, 0.75–0.97). On the other hand, biologics discontinuation was associated with prior adverse birth outcome (OR, 0.22, 95 percent CI, 0.05–0.95).

The present data highlight a potential gap in care of pregnant women with RA, according to the researchers. “With growing guidance on the management of pregnancies in RA, it is important to ensure translation of clinical knowledge to women who are making important medication-taking decisions during pregnancy.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 5 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 4 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.